Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.58 |
| ▸ | DRD4 | P21917 | 2/20 | 0.58 |
| ▸ | DRD3 | P35462 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | PDE6D | O43924 | 1/20 | 0.55 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.55 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | ESR1 | P03372 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3496467 | 1.00 | DRD2 (0.58) | DRD2DRD4DRD3ALDH1A1PDE6D | |
| SCHEMBL3496157 | 0.99 | DRD2 (0.60) | DRD2DRD4DRD3ALDH1A1PDE6D | |
| SCHEMBL3498762 | 0.84 | DRD2 (0.51) | DRD2DRD4DRD3ALDH1A1ESR1 | |
| SCHEMBL3498439 | 0.84 | DRD2 (0.51) | DRD2DRD4DRD3ALDH1A1ESR1 | |
| SCHEMBL3498561 | 0.83 | ALDH1A1 (0.55) | DRD2DRD4DRD3ALDH1A1TP53 | |
| SCHEMBL3496085 | 0.83 | PRKACA (0.48) | DRD2DRD4DRD3MEN1KMT2A | |
| SCHEMBL3496759 | 0.83 | TP53 (0.51) | DRD2DRD4DRD3ALDH1A1PDE6D | |
| SCHEMBL3497905 | 0.83 | TP53 (0.51) | DRD2DRD4DRD3ALDH1A1PDE6D | |
| SCHEMBL3498756 | 0.83 | HRH3 (0.48) | DRD2DRD4DRD3ALDH1A1ESR1 | |
| SCHEMBL3497458 | 0.82 | ALDH1A1 (0.54) | DRD2DRD4DRD3ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803825-B2 | Aminoalkylazole derivatives as histamine-3 antagonists | WYETH LLC (US) | 2010-09-28 | — | — | US | claimed |
| EP-2170875-A1 | AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | Wyeth LLC (US) | 2010-04-07 | — | — | EP | claimed |
| US-20090023707-A1 | AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-01-22 | — | — | US | claimed |
| WO-2009012252-A1 | AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-01-22 | — | — | WO | claimed |
| US-7803825-B2 | Aminoalkylazole derivatives as histamine-3 antagonists | WYETH LLC (US) | 2010-09-28 | — | — | US | disclosed |
| EP-2170875-A1 | AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | Wyeth LLC (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009012252-A1 | AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-01-22 | — | — | WO | disclosed |
| US-20090023707-A1 | AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023707-A1 | AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | HRH4, HRH3, HRH2 | DRD2 419/4885DRD4 1020/4885DRD3 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.